Nazleen Hatim Bharmal, MD
Internal Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
- Since medical school
- 22 years
- Harvard Medical School, 2004
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bharmal’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A99524 · Current
Licensed to practise in California · since 2024 · expires 2028-08-31 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$4,702
Medicare paid this office $4,702 for 77 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 46 | $2,577 | $47 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 15 | $447 | $30 |
Who their Medicare patients are
77 Original Medicare patients in 2024. Average age 74 · Women 68% · Health risk score 1.19. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Chronic kidney disease 30% · Depression 27% · Diabetes 26% · Coronary heart disease 21% · Atrial fibrillation 18% · Stroke 17% · Heart failure 16% · Cancer 14%.
The office billed $64,804, Medicare allowed $7,412 and paid $4,702; for 125 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 77 | 125 | 74 | 1.19 | $64,804 | $4,702 |
| 2023 | 79 | 154 | 74 | 1.24 | $61,171 | $7,522 |
| 2022 | 85 | 162 | 71 | 1.51 | $62,167 | $8,540 |
| 2021 | 109 | 173 | 73 | 1.75 | $59,207 | $7,535 |
| 2020 | 104 | 152 | 71 | 1.69 | $50,489 | $6,652 |
| 2019 | 48 | 62 | 69 | 1.30 | $23,163 | $3,065 |
| 2014 | 62 | 78 | 72 | 1.66 | $15,205 | $1,780 |
| 2013 | 162 | 227 | 74 | 1.97 | $40,650 | $6,647 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 62 | $4,451 | $49 |
| Short return visit (20+ min) | 25 | $1,289 | $43 |
2022: 3 services
| Return visit (30+ min) | 68 | $5,436 | $49 |
| Long return visit (40+ min) | 15 | $1,103 | $74 |
| Short return visit (20+ min) | 15 | $675 | $42 |
2021: 2 services
| Return visit (30+ min) | 73 | $4,783 | $43 |
| Short return visit (20+ min) | 31 | $720 | $23 |
2020: 3 services
| Return visit (30+ min) | 57 | $3,255 | $39 |
| New patient visit (45+ min) | 15 | $1,235 | $82 |
| Short return visit (20+ min) | 21 | $669 | $29 |
2019: 1 service
| Return visit (30+ min) | 37 | $2,056 | $44 |
2014: 2 services
| Short return visit (20+ min) | 31 | $1,254 | $30 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 21 | $19 | $1 |
2013: 3 services
| Short return visit (20+ min) | 69 | $3,861 | $39 |
| Return visit (30+ min) | 18 | $1,277 | $58 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 69 | $615 | $7 |
Medicaid work
$851 in 2024
Medicaid paid $851 for 36 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 36 | $851 |
| 2024 | 36 | 1 | 17 | $851 |
| 2022 | 156 | 2 | 19 | $10,709 |
| 2021 | 238 | 4 | 18 | $14,492 |
| 2020 | 20 | 1 | 18 | $1,966 |
See the largest Medicaid services in earlier years
2022
| Hospital outpatient clinic visit for assessment and management of a patient | 87 | $8,507 |
| Return visit (30+ min) | 69 | $2,203 |
2021
| Hospital outpatient clinic visit for assessment and management of a patient | 122 | $11,582 |
| Return visit (30+ min) | 76 | $2,217 |
| Short return visit (20+ min) | 27 | $673 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 13 | $21 |
2020
| Hospital outpatient clinic visit for assessment and management of a patient | 20 | $1,966 |
Drugs they prescribed that Part D paid
$241,956
Pharmacies billed $241,956 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,433 generic and 284 brand-name prescriptions · $241,956 in drug cost · 17 antibiotic prescriptions · 17 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 20 | $40,295 | $2,015 |
| Jardiance | 36 | $29,944 | $832 |
| Trulicity | 21 | $27,761 | $1,322 |
| Eliquis | 20 | $24,129 | $1,206 |
| Myrbetriq | 23 | $11,773 | $512 |
See all 47 drugs
| Ozempic | 20 | $40,295 | $2,015 |
| Jardiance | 36 | $29,944 | $832 |
| Trulicity | 21 | $27,761 | $1,322 |
| Eliquis | 20 | $24,129 | $1,206 |
| Myrbetriq | 23 | $11,773 | $512 |
| Farxiga | 11 | $9,529 | $866 |
| Lantus Solostar | 12 | $1,828 | $152 |
| Atorvastatin | 152 | $1,310 | $9 |
| Rosuvastatin | 67 | $795 | $12 |
| Albuterol Sulfate Hfa | 25 | $744 | $30 |
| Levothyroxine | 67 | $727 | $11 |
| Escitalopram | 33 | $690 | $21 |
| Tamsulosin | 50 | $661 | $13 |
| Gabapentin | 45 | $623 | $14 |
| Esomeprazole Magnesium | 14 | $566 | $40 |
| Chlorthalidone | 28 | $550 | $20 |
| Omeprazole | 28 | $517 | $18 |
| Nystatin | 15 | $466 | $31 |
| Amlodipine Besylate | 92 | $456 | $5 |
| Losartan | 46 | $379 | $8 |
| Famotidine | 14 | $355 | $25 |
| Pantoprazole | 28 | $347 | $12 |
| Fludrocortisone Acetate | 11 | $337 | $31 |
| Metoprolol | 15 | $324 | $22 |
| Potassium Chloride | 14 | $290 | $21 |
| Lisinopril | 46 | $284 | $6 |
| Venlafaxine Hcl Er | 11 | $263 | $24 |
| Oxybutynin Chloride | 13 | $254 | $20 |
| Carvedilol | 15 | $234 | $16 |
| Finasteride | 12 | $233 | $19 |
| Valsartan | 17 | $199 | $12 |
| Aripiprazole | 14 | $199 | $14 |
| Metformin Hcl Er | 53 | $188 | $4 |
| Fluticasone Propionate | 19 | $176 | $9 |
| Baclofen | 14 | $154 | $11 |
| Zonisamide | 13 | $153 | $12 |
| Olmesartan Medoxomil | 14 | $145 | $10 |
| Torsemide | 13 | $142 | $11 |
| Hydrochlorothiazide | 30 | $113 | $4 |
| Ibuprofen | 11 | $87 | $8 |
| Felodipine Er | 12 | $83 | $7 |
| Metformin | 19 | $77 | $4 |
| Spironolactone | 12 | $63 | $5 |
| Triamterene-Hydrochlorothiazid | 20 | $61 | $3 |
| Lisinopril-Hydrochlorothiazide | 14 | $35 | $3 |
| Citalopram Hbr | 12 | $20 | $2 |
| Trazodone | 14 | $10 | $1 |
Year by year
| 2024 | 1,733 | 158 | None | 16% | $241,956 |
| 2023 | 1,772 | 154 | None | 15% | $297,074 |
| 2022 | 1,639 | 143 | None | 17% | $253,173 |
| 2021 | 1,290 | 147 | 1% (13) | 12% | $150,539 |
| 2020 | 1,081 | 121 | 2% (18) | 13% | $70,238 |
| 2019 | 462 | 65 | None | None | $35,143 |
| 2018 | 38 | 15 | 0% (0) | None | $1,068 |
| 2015 | 19 | None | 0% (0) | None | $3,797 |
| 2014 | 284 | 35 | 10% (28) | None | $21,990 |
| 2013 | 253 | 42 | 12% (29) | None | $17,709 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 45 drugs
| Ozempic | 25 | $41,145 | $1,646 |
| Trulicity | 24 | $34,912 | $1,455 |
| Farxiga | 11 | $19,343 | $1,758 |
| Jardiance | 16 | $16,979 | $1,061 |
| Lantus Solostar | 11 | $8,704 | $791 |
| Symbicort | 13 | $4,949 | $381 |
| Atorvastatin | 148 | $1,985 | $13 |
| Lidocaine | 11 | $1,229 | $112 |
| Esomeprazole Magnesium | 17 | $1,106 | $65 |
| Losartan | 77 | $1,037 | $13 |
| Albuterol Sulfate Hfa | 18 | $1,031 | $57 |
| Tamsulosin | 37 | $939 | $25 |
| Levothyroxine | 51 | $900 | $18 |
| Rosuvastatin | 53 | $874 | $16 |
| Potassium Chloride | 15 | $794 | $53 |
| Metoprolol | 27 | $729 | $27 |
| Amlodipine Besylate | 94 | $713 | $8 |
| Gabapentin | 47 | $676 | $14 |
| Diclofenac | 12 | $596 | $50 |
| Metformin Hcl Er | 56 | $520 | $9 |
| Omeprazole | 21 | $448 | $21 |
| Chlorthalidone | 15 | $419 | $28 |
| Felodipine Er | 12 | $355 | $30 |
| Famotidine | 11 | $350 | $32 |
| Fluticasone Propionate | 24 | $344 | $14 |
| Lisinopril | 62 | $334 | $5 |
| Escitalopram | 21 | $324 | $15 |
| Carvedilol | 19 | $321 | $17 |
| Clopidogrel | 16 | $248 | $15 |
| Metformin | 25 | $247 | $10 |
| Hydrochlorothiazide | 49 | $212 | $4 |
| Hydroxyzine | 13 | $201 | $15 |
| Torsemide | 14 | $198 | $14 |
| Latanoprost | 19 | $198 | $10 |
| Alendronate | 11 | $195 | $18 |
| Triamterene-Hydrochlorothiazid | 21 | $180 | $9 |
| Spironolactone | 14 | $177 | $13 |
| Tizanidine | 11 | $170 | $15 |
| Zonisamide | 11 | $157 | $14 |
| Warfarin | 12 | $151 | $13 |
| Isosorbide Mononitrate Er | 12 | $144 | $12 |
| Synthroid | 11 | $123 | $11 |
| Metoprolol | 18 | $110 | $6 |
| Easy Touch Alcohol Prep Pads | 11 | $85 | $8 |
| Valsartan | 13 | $57 | $4 |
2022: 42 drugs
| Ozempic | 14 | $24,761 | $1,769 |
| Eliquis | 13 | $20,909 | $1,608 |
| Jardiance | 12 | $11,337 | $945 |
| Lantus Solostar | 13 | $8,963 | $689 |
| Symbicort | 11 | $4,148 | $377 |
| Esomeprazole Magnesium | 12 | $2,620 | $218 |
| Rosuvastatin | 27 | $2,443 | $90 |
| Insulin Lispro Kwikpen U-100 | 12 | $2,163 | $180 |
| Atorvastatin | 147 | $2,096 | $14 |
| Metoprolol | 30 | $1,224 | $41 |
| Levothyroxine | 39 | $991 | $25 |
| Diclofenac | 12 | $826 | $69 |
| Potassium Chloride | 20 | $770 | $39 |
| Albuterol Sulfate Hfa | 16 | $733 | $46 |
| Losartan | 51 | $725 | $14 |
| Azelastine | 15 | $527 | $35 |
| Amlodipine Besylate | 91 | $513 | $6 |
| Valsartan | 15 | $487 | $32 |
| Aripiprazole | 14 | $485 | $35 |
| Tamsulosin | 36 | $484 | $13 |
| Lisinopril | 74 | $436 | $6 |
| Metformin Hcl Er | 43 | $418 | $10 |
| Gabapentin | 39 | $401 | $10 |
| Chlorthalidone | 11 | $377 | $34 |
| Pantoprazole | 22 | $375 | $17 |
| Carvedilol | 44 | $365 | $8 |
| Fludrocortisone Acetate | 13 | $349 | $27 |
| Triamterene-Hydrochlorothiazid | 27 | $308 | $11 |
| Ibuprofen | 14 | $230 | $16 |
| Hydralazine | 12 | $226 | $19 |
| Warfarin | 14 | $209 | $15 |
| Famotidine | 13 | $205 | $16 |
| Fluticasone Propionate | 12 | $200 | $17 |
| Felodipine Er | 12 | $200 | $17 |
| Omeprazole | 13 | $188 | $14 |
| Metoprolol | 26 | $168 | $6 |
| Cyclobenzaprine | 13 | $166 | $13 |
| Synthroid | 11 | $159 | $14 |
| Clopidogrel | 13 | $137 | $11 |
| Hydrochlorothiazide | 36 | $132 | $4 |
| Metformin | 21 | $95 | $5 |
| Simvastatin | 11 | $92 | $8 |
2021: 30 drugs
| Symbicort | 11 | $3,760 | $342 |
| Atorvastatin | 97 | $2,250 | $23 |
| Metoprolol | 25 | $1,443 | $58 |
| Rosuvastatin | 17 | $1,017 | $60 |
| Valsartan | 18 | $1,003 | $56 |
| Albuterol Sulfate Hfa | 23 | $817 | $36 |
| Tamsulosin | 31 | $726 | $23 |
| Losartan | 40 | $722 | $18 |
| Levothyroxine | 19 | $574 | $30 |
| Diclofenac | 14 | $564 | $40 |
| Gabapentin | 37 | $560 | $15 |
| Chlorthalidone | 14 | $495 | $35 |
| Azelastine | 13 | $487 | $37 |
| Lisinopril | 81 | $445 | $5 |
| Triamterene-Hydrochlorothiazid | 31 | $370 | $12 |
| Amlodipine Besylate | 73 | $352 | $5 |
| Metformin Hcl Er | 24 | $292 | $12 |
| Potassium Chloride | 11 | $255 | $23 |
| Warfarin | 11 | $219 | $20 |
| Carvedilol | 28 | $208 | $7 |
| Fluticasone Propionate | 16 | $197 | $12 |
| Hydrochlorothiazide | 40 | $197 | $5 |
| Finasteride | 13 | $186 | $14 |
| Felodipine Er | 13 | $168 | $13 |
| Lisinopril-Hydrochlorothiazide | 12 | $168 | $14 |
| Simvastatin | 12 | $146 | $12 |
| Metformin | 28 | $126 | $5 |
| Furosemide | 14 | $77 | $6 |
| Cyclobenzaprine | 14 | $53 | $4 |
| Clopidogrel | 11 | $35 | $3 |
2020: 30 drugs
| Esomeprazole Magnesium | 16 | $2,417 | $151 |
| Eplerenone | 12 | $1,624 | $135 |
| Atorvastatin | 55 | $918 | $17 |
| Albuterol Sulfate Hfa | 16 | $717 | $45 |
| Gabapentin | 44 | $716 | $16 |
| Metoprolol | 27 | $657 | $24 |
| Rosuvastatin | 24 | $476 | $20 |
| Losartan | 32 | $470 | $15 |
| Diclofenac | 12 | $438 | $36 |
| Tamsulosin | 24 | $428 | $18 |
| Fluticasone Propionate | 20 | $327 | $16 |
| Omeprazole | 24 | $312 | $13 |
| Atenolol | 12 | $299 | $25 |
| Lisinopril | 47 | $293 | $6 |
| Amlodipine Besylate | 37 | $292 | $8 |
| Chlorthalidone | 11 | $276 | $25 |
| Levothyroxine | 16 | $253 | $16 |
| Valsartan | 11 | $219 | $20 |
| Metformin | 37 | $191 | $5 |
| Warfarin | 12 | $189 | $16 |
| Metformin Hcl Er | 13 | $157 | $12 |
| Montelukast | 22 | $157 | $7 |
| Pravastatin | 14 | $118 | $8 |
| Prednisone | 14 | $117 | $8 |
| Tizanidine | 15 | $98 | $7 |
| Allopurinol | 13 | $82 | $6 |
| Cyclobenzaprine | 19 | $81 | $4 |
| Finasteride | 17 | $64 | $4 |
| Sertraline | 12 | $45 | $4 |
| Carvedilol | 14 | $42 | $3 |
2019: 10 drugs
| Victoza 2-Pak | 11 | $6,906 | $628 |
| Proair Hfa | 11 | $717 | $65 |
| Gabapentin | 16 | $614 | $38 |
| Atorvastatin | 21 | $559 | $27 |
| Omeprazole | 15 | $270 | $18 |
| Amlodipine Besylate | 11 | $246 | $22 |
| Lisinopril | 22 | $159 | $7 |
| Tizanidine | 11 | $129 | $12 |
| Montelukast | 12 | $73 | $6 |
| Metformin | 16 | $51 | $3 |
2014: 8 drugs
| Duloxetine | 14 | $2,392 | $171 |
| Diovan | 11 | $1,509 | $137 |
| Atorvastatin | 11 | $233 | $21 |
| Acetaminophen-Codeine | 13 | $205 | $16 |
| Simvastatin | 16 | $100 | $6 |
| Amlodipine Besylate | 22 | $96 | $4 |
| Cyclobenzaprine | 13 | $94 | $7 |
| Hydrochlorothiazide | 16 | $65 | $4 |
2013: 4 drugs
| Oxycodone | 13 | $890 | $68 |
| Atorvastatin | 17 | $715 | $42 |
| Famotidine | 12 | $160 | $13 |
| Amlodipine Besylate | 17 | $159 | $9 |
Professional record
- NPI
- 1306900402
- Licence
- CA A99524California A99524: Current · expires 2028-08-31
- Trained
- Harvard Medical School, 2004 · 22 years ago
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-12-21
- NPI last updated
- 2024-11-07
- NPI record certified
- 2024-11-07
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: UCLA Iris Cantor Womens Health Ctr, Los Angeles, CA, 90095